Lenabasum is under clinical development by Corbus Pharmaceuticals and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData, Phase II drugs for Systemic Lupus Erythematosus have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lenabasum’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Lenabasum overview

Lenabasum is under development for the treatment of systemic lupus erythematosus, diffuse cutaneous systemic sclerosis. It is an oral endo cannabinoid mimetic. The drug candidate acts by targeting cannabinoid receptor 2 (CB2). JBT-101 a nanomolar cannabinoid and is based on the core structure of Tetrahydrocannabinol (THC). It was under development for the treatment of bladder pain, inflammatory disorders and bladder overactivity in hypersensitive bladder disorders such as interstitial cystitis, cystic fibrosis, skin-predominant dermatomyositis and neuropathic pain. It is a new chemical entity (NCE). 

Corbus Pharmaceuticals overview

Corbus Pharmaceuticals is a clinical-stage pharmaceutical company that develops and commercializes novel therapeutics to treat inflammatory and fibrotic diseases. The company’s pipeline product portfolio includes Lenabasum, an oral small-molecule for the treatment of inflammatory diseases; CRB-4001, to treat fibrotic diseases. It serves in the therapeutic areas of chronic inflammation, autoimmune diseases, allergies and orphan diseases. Corbus Pharmaceuticals collaborates with National Institutes of Health (NIH) for in the development of drugs. The company has operations in Europe, Israel, and Australia. Corbus Pharmaceuticals is headquartered in Norwood, Massachusetts, the US.

For a complete picture of Lenabasum’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.